Litcius/Paper detail

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Luis Paz‐Ares, David Vicente, Ali Tafreshi, Andrew Robinson, Héctor Soto Parrà, Julien Mazières, Bárbara Hermes, İrfan Çiçin, Balazs Medgyasszay, Jerónimo Rafael Rodríguez‐Cid, Isamu Okamoto, Sung-Sook Lee, Rodryg Ramlau, Vladimir Vladimirov, Ying Cheng, Xuan Deng, Ying Zhang, Tuba Öcek Baş, Bilal Piperdi, Balázs Halmos

2020Journal of Thoracic Oncology647 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePembrolizumabOncologyPlaceboProtocol (science)Internal medicineChemotherapyRandomized controlled trialImmunotherapyCancerPathologyAlternative medicineCancer Immunotherapy and BiomarkersImmune cells in cancerColorectal and Anal Carcinomas
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 | Litcius